Employing a conjugatable diamidobenzimidazole (diABZI) STING agonist as a clinically relevant example, we demonstrate that nanobody hitchhiking of STING agonists on serum albumin dramatically improves their pharmacological properties and increases tumor accumulation, leading to a reduction in tumor burden and improved therapeutic outcomes in multiple mouse tumor models. The gene discussed is STING1; the disease is neoplasm.